IMPORTANT SAFETY INFORMATION

Zenzedi (dextroamphetamine sulfate tablets, USP) is a federally controlled substance (CII) with a high risk of abuse or dependence. Prolonged use may lead to drug dependence and must be avoided. Subjects may obtain Zenzedi for non-therapeutic use or distribution to others, and it should be prescribed or dispensed sparingly.

Misuse of Zenzedi may cause sudden death and serious cardiovascular adverse events.

Zenzedi® (dextroamphetamine sulfate, USP)
This site is intended for US residents only.
Indication: Zenzedi (dextroamphetamine sulfate tablets, USP) is a prescription medicine for the treatment of Narcolepsy. Zenzedi is also indicated as a treatment for ADHD in pediatric patients ages 3 to 16 years as an integral part of a total treatment program for ADHD that may include counseling or other therapies.

Every ADHD Patient’s Needs Are Different

IMPORTANT SAFETY INFORMATION

Zenzedi® (dextroamphetamine sulfate tablets, USP) is a central nervous system (CNS) stimulant prescription medicine used for the treatment of:

  • A sleep disorder called narcolepsy.
  • Attention-Deficit Hyperactivity Disorder (ADHD) in children 3 to 16 years of age. Zenzedi may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Zenzedi is safe and effective in children under 3 years of age.

Zenzedi is a federally controlled substance (CII) because it contains dextroamphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep Zenzedi in a safe place to protect it from theft. Never give your Zenzedi to anyone else because it may cause death or harm them. Selling or giving away Zenzedi may harm others and is against the law.

WARNING: ABUSE, MISUSE, AND ADDICTION

Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine sulfate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine sulfate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

ADDITIONAL IMPORTANT SAFETY INFORMATION

Do not take Zenzedi if you or your child:

  • are allergic to amphetamine products or any of the ingredients in Zenzedi.
  • are taking or have taken within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI), including the antibiotic linezolid or the intravenous medicine methylene blue.

What is the most important information I should know about Zenzedi?

Zenzedi may cause serious sides effects, including:

Abuse, misuse, and addiction. Zenzedi has a high potential for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Zenzedi, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Zenzedi or when it is used in ways that are not approved, such as snorting or injection.

  • Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with Zenzedi and will monitor you or your child during treatment.
  • Zenzedi may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.
  • Do not give Zenzedi to anyone else.
  • Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Risks for people with serious heart problems: Sudden death has happened in people who have heart defects or other serious heart disease.

Your healthcare provider should check you or your child carefully for heart problems before starting treatment with Zenzedi. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.

Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Zenzedi.

Increased blood pressure and heart rate. Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with Zenzedi.

Mental (psychiatric) problems can occur including:

  • new or worsening behavior or thought problems
  • new or worsening bipolar illness
  • new psychotic symptoms (such as hearing voices, or seeing, or believing things that are not real) or new manic symptoms

Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.

Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with Zenzedi, especially hearing voices, seeing, or believing things that are not real, or new manic symptoms.

Before taking Zenzedi, tell your healthcare provider about all of your or your child’s medical conditions, including if you or your child:

  • have heart problems, heart disease, heart defects, or high blood pressure
  • have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression
  • have seizures or have had an abnormal brain wave test (EEG)
  • have circulation problems in fingers and toes
  • have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome
  • are pregnant or plan to become pregnant. It is not known if Zenzedi will harm the unborn baby. Tell your healthcare provider if you or your child become pregnant during treatment with Zenzedi.
  • are breastfeeding or plan to breastfeed. Zenzedi passes into breast milk. You or your child should not breastfeed during treatment with Zenzedi. Talk to your healthcare provider about the best way to feed the baby during treatment with Zenzedi.

Tell your healthcare provider about all of the medicines that you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Zenzedi and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with Zenzedi. Your healthcare provider will decide if Zenzedi can be taken with other medicines.

Especially tell your healthcare provider if you or your child take:

  • selective serotonin reuptake inhibitors (SSRIs)
  • medicines used to treat migraine headaches called triptans
  • lithium
  • tramadol
  • buspirone
  • serotonin norepinephrine reuptake inhibitors (SNRIs)
  • tricyclic antidepressants
  • fentanyl
  • tryptophan
  • St. John’s Wort

Know the medicines that you or your child take. Keep a list of your or your child’s medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine. Do not start any new medicine during treatment with Zenzedi without talking to your healthcare provider first.

What should I avoid while taking Zenzedi?

  • Do not drive, operate heavy machinery, or do other potentially dangerous activities until you know how Zenzedi affects you.

What are possible side effects of Zenzedi?

Zenzedi may cause serious side effects, including:

  • Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with Zenzedi. Your healthcare provider may stop your child’s Zenzedi treatment if they are not growing or gaining weight as expected.
  • Seizures. Your healthcare provider may stop treatment with Zenzedi if you or your child have a seizure.
  • Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Signs and symptoms may include:
    • fingers or toes may feel numb, cool, painful
    • fingers or toes may change color from pale, to blue, to red

Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.

Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Zenzedi.

  • New or worsening tics or worsening Tourette’s syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with Zenzedi.
  • Serotonin syndrome. This problem may happen when Zenzedi is taken with certain other medicines and may be life-threatening. Stop taking Zenzedi and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome:
    • agitation
    • fast heartbeat
    • flushing
    • seizures
    • coma
    • sweating
    • loss of coordination
    • confusion
    • dizziness
    • tremors, stiff muscles, or muscle twitching
    • seeing or hearing things that are not real (hallucination)
    • changes in blood pressure
    • high body temperature (hypothermia)
    • nausea, vomiting, diarrhea

The most common side effects of Zenzedi include:

  • fast heartbeat
  • decreased appetite
  • tremors
  • headache
  • trouble sleeping
  • dizziness
  • stomach upset
  • weight loss
  • dry mouth

These are not all the possible side effects of Zenzedi. Please see Full Prescribing Information for a full list.

The Important Safety Information does not include all the information needed to use Zenzedi safely and effectively. Please see accompanying full Prescribing Information for Zenzedi.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc.
at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PP-ZEN-US-0097